TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Urine total protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urine albumin excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Response rates in treatment of acute exacerbations of schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to 25% of patients experiencing a recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: feelings of exclusion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FEV1 at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV1 area under the curve from 0-4 h post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total COPD symptom score after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: adeptness at laparoscopic urethrovesical anastomosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fasting capillary blood glucose cut-off for undiagnosed diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COHb half-lives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical efficacy of rituximab in RA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquisition of S aureus
Endpoint domain: Adverse events/effects
Primary endpoint: Colonization with Pseudomonas aeruginosa
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical outcome measures (including radiographic and pulmonary function)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SCL90 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of clinical benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck Disability Index (NDI) success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preoperative discomfort
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Binge drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Very heavy drinking sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants tested for blood borne infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Attendance for STI screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Visuospatial working memory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite of cardiovascular mortality, heart failure, thrombo-embolic complications, bleeding, serious adverse effects of antiarrhythmic drugs and pacemaker implants
Endpoint domain: Mortality/survival
Primary endpoint: Leukocytes in expressed prostatic secretion (LEPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sperm viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mild transient hypoxemia
Endpoint domain: Adverse events/effects
Primary endpoint: Invasive fungal infections
Endpoint domain: Adverse events/effects
Primary endpoint: Cryptococcosis
Endpoint domain: Adverse events/effects
Primary endpoint: Esophageal candidiasis
Endpoint domain: Adverse events/effects
Primary endpoint: Shade matching scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mammogram uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of patients who improved their condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved NYHA class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: small-bowel cleansing level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial fibrillation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Length of in-hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Frequency of fecal incontinent episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to defer defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal incontinence-specific quality of life assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: biliary tract surgery
Endpoint domain: Adverse events/effects
Primary endpoint: mortality due to pulmonary embolism
Endpoint domain: Mortality/survival
Primary endpoint: ED50 of 0.5% hypobaric bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED50 of 0.5% hypobaric ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of Delayed Onset Muscle Soreness (DOMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biopsy-proven acute rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Estimated patient survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Movement function scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to walk independently
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: problem-solving coping
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: survival free from ICD therapy
Endpoint domain: Mortality/survival
Primary endpoint: Gingival thickness increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with aesthetics
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nephrotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: wound-related quality of life (wound-QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: cigarette harm perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Choice to intensify therapy by initiating etanercept
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of runny nose/nasal congestion
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity by hemagglutination inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity by microneutralization assays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma metHb levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: plasma haemoglobin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: daily pain relief scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily pain intensity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: depression mean scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PES (Patient Esthetic Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in aspartate transaminase (AST) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in alanine transaminase (ALT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nursing time for IV administration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost related to IV fluids
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tooth color change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAI‐1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: VWF level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: tPA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: serum vitamin A level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum complement C3 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum sIgA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse events severity
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax and AUC0-infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N2 latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GZ value in d2 test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: preterm birth rate
Endpoint domain: Mortality/survival
Primary endpoint: newborn intensive care unit admission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean neonatal length of stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to CRC screening
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean inspiratory flow rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: In vitro delivered doses (DDs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fine particle doses (FPDs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Increase in treatment team's confidence in management plan
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post Traumatic Stress Disorder Symptom Scale (PSS‐SR) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elevated serum uric acid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gastric ulcer healing rates at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Microbial load in treated axilla
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Umbilical arterial blood gas determinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration‐time curve to last measurable drug concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC to infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: net ultrafiltration (UF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peritoneal clearance of creatinine and urea nitrogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum O(2) uptake (Vo(2)max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfactory results
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Victorian Institute of Sports Assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anagen hair rate in occipital hair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anagen hair rate in frontal hair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ischaemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of lidocaine as a local anesthetic for facial lacerations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial fibrillation occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of brain natriuretic peptide and ischemic biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Advanced neoplasia yield per 100 CTC participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Immediate recurrence of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Eradication of metronidazole resistant H. pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intent-to-treat cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle-Brachial Index (ABI) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Delayed initiation of sexual intercourse
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Correct knowledge about emergency contraception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Received condoms from parents
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: change in severity of AD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extent of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean postoperative serum Na(+) decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant transurethral resection syndrome cases
Endpoint domain: Adverse events/effects
Primary endpoint: Urethral strictures observed
Endpoint domain: Adverse events/effects
Primary endpoint: Insomnia score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Cost effectiveness of the SIMPle intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: maximal platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: thromboxane B2 (TxB2) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: good outcome 3 months poststroke
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postoperative Acute Renal Failure (ARF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mortality associated with ARF
Endpoint domain: Mortality/survival
Primary endpoint: quit rate for adherent participants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: insomnia levels
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: tests performed per patient day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: general health functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: self-management behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Production of tumor necrosis factor by macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of plasma protein (albumin) binding to PGE2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of infections in AD/ACLF
Endpoint domain: Adverse events/effects
Primary endpoint: Change in arterial PCO2 (ΔPavCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Eradication rate of H pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tooth-whitening efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bleaching tolerability severity-days
Endpoint domain: Adverse events/effects
Primary endpoint: CPT-induced change in luminal area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: salivary TNF‐α levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Margin reflex distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: symptom resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coping removal stresses (MPa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in the number of reticulocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total enzyme release
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficult intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Transillumination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased confidence in airway management
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: increased skill in airway management
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean stool sodium content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean urinary sodium content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean stool phosphorus content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative bioavailability of crushed rivaroxaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CIP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced risk of birth before 28 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Use of blood cardioplegia in infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Facility delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance for at least one antenatal care visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance for at least one postnatal care visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum change in SBP from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of significant change in SBP, DBP, and MAP from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total ED of the new TRO‐CTA protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of CM used for the new TRO‐CTA protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNR of the AAo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vascular death/myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy in predicting prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy in predicting high-grade cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor anti-progressive effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cytomegalovirus reactivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: one-month mortality
Endpoint domain: Mortality/survival
Primary endpoint: Major Histological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AI malignant probability for diagnosing malignancies of IPMNs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: SIF (Serum Insulin Factor)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of episodes of intraoperative hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peripheral microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of completion of THRIVE
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Relevance of information provided by THRIVE
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recommendation of THRIVE to a friend
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Durability of inlays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of risedronate absorption (AUC and Ae)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of absorption (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum PIIINP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative incidence of hypothyroidism (HT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes